🇺🇸 FDA
Pipeline program

Novel Supplement Based Therapy

SIBO-ATRGM2017

Phase 1 other terminated

Quick answer

Novel Supplement Based Therapy for Small Intestinal Bacterial Overgrowth is a Phase 1 program (other) at Atrium Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Atrium Therapeutics
Indication
Small Intestinal Bacterial Overgrowth
Phase
Phase 1
Modality
other
Status
terminated

Clinical trials